Safety of live attenuated herpes zoster vaccine in adults 70–79 years: A self-controlled case series analysis using primary care data from Australia’s MedicineInsight program
Open Access
- 11 April 2020
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 38 (23), 3968-3979
- https://doi.org/10.1016/j.vaccine.2020.03.054
Abstract
No abstract availableFunding Information
- National Centre for Immunisation Research and Surveillance
- Australian Government Department of Health
- National Health and Medical Research Council
- Royal Australasian College of Physicians
- Career Development Fellowship from the National Health and Medical Research Council (GNT1111657)
This publication has 33 references indexed in Scilit:
- Similar herpes zoster incidence across Europe: results from a systematic literature reviewBMC Infectious Diseases, 2013
- Safety of Zostavax™—A cohort study in a managed care organizationVaccine, 2012
- Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 YearsClinical Infectious Diseases, 2012
- Safety and tolerability of zoster vaccine in adults ≥60 years oldHuman Vaccines, 2011
- Safety of zoster vaccine in adults from a large managed‐care cohort: a Vaccine Safety Datalink studyJournal of Internal Medicine, 2011
- Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in AustraliaVaccine, 2011
- Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatmentThe Lancet Neurology, 2009
- Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and olderVaccine, 2009
- The incidence of herpes zoster in a United States administrative databaseJournal of General Internal Medicine, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsThe New England Journal of Medicine, 2005